Sector News

Actelion CEO says has received no takeover approaches

October 21, 2014
Life sciences
(Reuters) – Actelion has received no takeover bids from interested parties, the company’s chief executive said on Tuesday.
 
Analysts have in the past touted Actelion as a potential takeover target, since its healthy pipeline drugs to treat pulmonary arterial hypertension could draw U.S. bidders seeking to lower their tax bill by moving their tax base to Switzerland, a tactic known as inversion.
 
But last month’s rule changes by the U.S. Treasury Department aimed at curtailing such deals has prompted several pharmaceutical companies, including AbbVie, to ditch original M&A plans.
 
Asked by Reuters whether Actelion has been approached by any interested parties, the company’s Chief Executive Jean-Paul Clozel said, “No.”
 
Speaking after Actelion published third-quarter results that beat expectations, Clozel said the biotech firm wanted to increase shareholder returns and grow ahead of the market at the same time.
 
(Reporting by Caroline Copley)

comments closed

Related News

April 20, 2024

CureVac and MD Anderson Cancer Center partner to develop new cancer vaccines

Life sciences

CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.

April 20, 2024

FUJIFILM plans $1.2 billion investment in major US manufacturing facility

Life sciences

FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.

April 20, 2024

Sanofi cuts staff in Belgium as early-stage research dwindles

Life sciences

Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.

How can we help you?

We're easy to reach